|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02162 KEYMED BIO-B
Nominal 
43.650 +2.100 (+5.054%) | 2024/06 - Interim RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | (303,620) | (401,934) | (214,637) | (119,361) |
| Net Cash from / (used in) Investing Activities | -- | 468,203 | (645,586) | (2,035,879) | (113,067) |
| Net Cash from / (used in) Financing Activities | -- | 72,131 | (8,059) | 3,638,376 | 7,397 |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | 236,714 | (1,055,579) | 1,387,860 | (225,031) |
| Cash & Cash Equivalents at beginning of period | -- | 604,070 | 1,520,619 | 199,409 | 432,608 |
| Effect of Foreign Exchange Rate Changes | -- | 10,245 | 139,030 | (66,650) | (8,168) |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 851,029 | 604,070 | 1,520,619 | 199,409 |
| Remarks: | Real time quote last updated: 01/11/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -336,745,000 |
| %Change | -- |
| EPS / (LPS) | RMB -1.290 |
| NBV Per Share (¥) | RMB 9.426 |